Go back to News
NEWS
GA_P advises SPAC Gesher I Acquisition on its merger with Freightos
8 of June, 2022
Gómez-Acebo & Pombo has advised NASDAQ-listed SPAC Gesher I Acquisition Corp (GIAC) on its merger agreement with Freightos Ltd, which includes Spain’s WebCargo. The value of the transaction is about $435m.
Freightos is a global digital freight booking services platform. As part of the transaction, Freightos has secured $80m in capital commitments. The capital raised from the transaction will be invested to further expand the business, drive transaction value and improve margins.
Advising on the transaction were: David González, Samara Schaar and Rodrigo Fernández, Corporate partner and associates; Bárbara Sáinz, Isabel Bandín, Claudia Pérez and Irantze Irrigain, Intellectual Property associates; Lourdes Escassi, Clara Juanola and Natalia Mestres, Labour associates; Mariana Díaz-Moro and Carla Fandiño, Tax partner and associate; and Juan Vera, Real Estate associate.
Freightos is a global digital freight booking services platform. As part of the transaction, Freightos has secured $80m in capital commitments. The capital raised from the transaction will be invested to further expand the business, drive transaction value and improve margins.
Advising on the transaction were: David González, Samara Schaar and Rodrigo Fernández, Corporate partner and associates; Bárbara Sáinz, Isabel Bandín, Claudia Pérez and Irantze Irrigain, Intellectual Property associates; Lourdes Escassi, Clara Juanola and Natalia Mestres, Labour associates; Mariana Díaz-Moro and Carla Fandiño, Tax partner and associate; and Juan Vera, Real Estate associate.
Lawyer mentioned
David González – Partner
Samara Schaar – Senior associate
See all lawyers
See less lawyers
Tipology
Deal
Press contact
Director of Business Development, Marketing and Communications
Director of Business Development, Marketing and Communications
More information about
Gómez-Acebo & Pombo
03 Mar, 2026 
PUBLICATION
26 Feb, 2026
Pharma & Healthcare No. 47
The newsletter covers the main developments in Pharma & Healthcare legislation and case law.
26 Feb, 2026 
PUBLICATION
23 Feb, 2026
Irregularities in public sector staffing. Jurisdiction and/or substantive law
When a serious irregularity is found in administrative contracts owing to their employment character, jurisdiction lies with the employment branch of the court system. However, if the administrative route is not outside the scope of the law, jurisdiction lies with the judicial review branch of the court system.
23 Feb, 2026
PUBLICATION
13 Feb, 2026
Senior management, membership of the board of directors and insolvency proceedings: single association theory yes, but also employer-employee relationship
Despite classifying the association as a commercial relationship and not an employment relationship, compensation amounts for termination of contract are allowed if they match those accepted by the insolvency practitioners, just as remuneration amounts are allowed if said practitioners had decided to accept remuneration in some months but not in others.
13 Feb, 2026
PUBLICATION
09 Feb, 2026
Notarial enforcement of pledges. Is Article 1872 of the Civil Code mandatory? In what sense?
The clause agreed upon must comply, for greater certainty, with the provisions of the new judicial enforcement procedure. It will be necessary to agree on an appraised value, which is not required in Article 1872 CC, because otherwise the award would be similar to a ‘forfeiture proviso’ (pactum commissorium), which the Civil Code neutralised with the drastic imposition of extinguishment of the debt in its entirety.
09 Feb, 2026
PUBLICATION
06 Feb, 2026
Automotive and Sustainable Mobility No. 29
Summary of legislative and jurisprudential developments relating to the automotive sector.
06 Feb, 2026
PUBLICATION
29 Jan, 2026
On Call Protocol for the Alimentaria and Hostelco 2026 Trade Fairs
In preparation for the Alimentaria and Hostelco 2026 trade fairs, the Commercial Section of the Barcelona First Instance Court has approved a rapid response protocol to deal promptly with any potential conflicts relating to intellectual and industrial property rights (patents,trademarks, designs, and copyright), as well as trade secrets and unfair competition issues that may arise during these events.
29 Jan, 2026
PUBLICATION
27 Jan, 2026
Jurisdiction of national courts of States party to the Agreement on a Unified Patent Court in respect of actions relating to classic European patents during the transitional period
During the transitional period of the Agreement on a Unified Patent Court, national courts retain jurisdiction to hear cases concerning classic European patents, without the need for the proprietor to have exercised the opt-out option, i.e. without the need to have excluded the jurisdiction of the Unified Patent Court over such patents. However, the Venice Court ruling discussed here considers that national courts may only be used if the opt-out has been exercised, contradicting the provisions of Article 83 of the Agreement.
27 Jan, 2026
PUBLICATION
21 Jan, 2026
Incompatibility between practising a healthcare profession and having a pecuniary interest in the manufacture or sale of medicinal products or medical devices
Royal Legislative Decree 1/2015, of 24 July, approving the recast version of the Medicinal Products and Medical Devices (Guarantees and Rational Use) Act, prohibits healthcare professionals with prescribing powers from having a direct pecuniary interest in activities related to medicines. This prohibition does not extend to indirect interests, as distinguished in Article 4 of said legislative decree. Judgment no. 483/2025 of the High Court of Justice of the Basque Country concludes that mere membership of a group of companies does not entail incompatibility if each entity retains real autonomy.
21 Jan, 2026
PUBLICATION
15 Jan, 2026
Excessive extension of the Bolar clause in the 'pharmaceutical legislative package'
The Bolar clause allows studies and trials necessary to obtain marketing authorisations for medicinal products to be carried out without infringing patents. Its scope has grown during the passage of the pharmaceutical legislative package, incorporating more actors and more activities, to include participation in public tenders before the patent expires. This extension raises questions about compatibility with the TRIPS Agreement, which only allows limited exceptions to patent rights. Participation in tenders could be considered an offer to sell, thus violating the limits set by that agreement.
15 Jan, 2026